Patents Assigned to Immunex Corporation
-
Patent number: 8715683Abstract: Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.Type: GrantFiled: February 12, 2013Date of Patent: May 6, 2014Assignee: Immunex CorporationInventor: Dirk M Anderson
-
Publication number: 20140093956Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.Type: ApplicationFiled: December 3, 2013Publication date: April 3, 2014Applicant: IMMUNEX CORPORATIONInventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
-
Patent number: 8679487Abstract: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.Type: GrantFiled: July 1, 2010Date of Patent: March 25, 2014Assignee: Immunex CorporationInventors: Richard J. Armitage, Jose Carlos Escobar, Arvia E. Morris
-
Patent number: 8674078Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.Type: GrantFiled: April 10, 2012Date of Patent: March 18, 2014Assignee: Immunex CorporationInventors: Peter R. Baum, Sabine S. Escobar, Joanne L. Viney
-
Patent number: 8569456Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.Type: GrantFiled: March 19, 2012Date of Patent: October 29, 2013Assignee: Immunex CorporationInventors: Dirk M Anderson, Laurent Galibert, Eugene Maraskovsky
-
Patent number: 8529894Abstract: The invention pertains to methods of treating cardiovascular disease by modulating inflammatory and immunoregulatory responses associated with such pathological conditions. Embodiments of the invention provide methods for the treatment of cardiovascular disease in a subject having cardiovascular disease comprising administering an effective amount of one or more IL-17 antagonists, IL-18 antagonists, 4-1BB antagonists, CD30 antagonists, OX40 antagonists and/or CD39 alone or in any combination. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).Type: GrantFiled: June 26, 2012Date of Patent: September 10, 2013Assignee: Immunex CorporationInventors: Paul B. J. Burton, Theresa A. Deisher
-
Publication number: 20130224189Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: ApplicationFiled: March 1, 2013Publication date: August 29, 2013Applicant: IMMUNEX CORPORATIONInventor: IMMUNEX CORPORATION
-
Publication number: 20130225490Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: ApplicationFiled: May 6, 2013Publication date: August 29, 2013Applicant: IMMUNEX CORPORATIONInventors: John Ernest Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Armstrong
-
Publication number: 20130203682Abstract: Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.Type: ApplicationFiled: February 12, 2013Publication date: August 8, 2013Applicant: IMMUNEX CORPORATIONInventor: Immunex Corporation
-
Publication number: 20130164287Abstract: The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNF? by administering a TNF? antagonist, such as recombinant TNFR:Fc.Type: ApplicationFiled: February 21, 2013Publication date: June 27, 2013Applicant: IMMUNEX CORPORATIONInventor: Immunex Corporation
-
Patent number: 8444979Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: September 23, 2011Date of Patent: May 21, 2013Assignee: Immunex CorporationInventors: John E Sims, Stewart D Lyman, Hilary J McKenna, Allison P Armstrong
-
Publication number: 20130101585Abstract: Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.Type: ApplicationFiled: December 17, 2012Publication date: April 25, 2013Applicant: IMMUNEX CORPORATIONInventor: Immunex Corporation
-
Publication number: 20130095549Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: ApplicationFiled: December 19, 2012Publication date: April 18, 2013Applicant: IMMUNEX CORPORATIONInventor: IMMUNEX CORPORATION
-
Patent number: 8414895Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: October 6, 2010Date of Patent: April 9, 2013Assignee: Immunex CorporationInventors: Kristine M. Kim, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
-
Publication number: 20130084603Abstract: The invention is directed to B7L-1 as a purified and isolated protein, the DNA encoding the B7L-1, host cells transfected with cDNAs encoding B7L-1 and processes for preparing B7L-1 polypeptides.Type: ApplicationFiled: December 4, 2012Publication date: April 4, 2013Applicant: IMMUNEX CORPORATIONInventor: IMMUNEX CORPORATION
-
Patent number: 8410060Abstract: The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNF? by administering a TNF? antagonist, such as recombinant TNFR:Fc.Type: GrantFiled: February 6, 2012Date of Patent: April 2, 2013Assignee: Immunex CorporationInventor: Barbara K. Finck
-
Patent number: 8410252Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: August 24, 2010Date of Patent: April 2, 2013Assignee: Immunex CorporationInventors: David J Cosman, Jurgen Mullberg, William C Fanslow, III, Marek Z Kubin, Richard J Armitage
-
Patent number: 8377690Abstract: Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.Type: GrantFiled: June 15, 2010Date of Patent: February 19, 2013Assignee: Immunex CorporationInventor: Dirk M Anderson
-
Patent number: 8361466Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: March 31, 2010Date of Patent: January 29, 2013Assignee: Immunex CorporationInventor: Steven R. Wiley
-
Patent number: 8333963Abstract: Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.Type: GrantFiled: August 4, 2010Date of Patent: December 18, 2012Assignee: Immunex CorporationInventors: Dirk M Anderson, Laurent J Galibert